News

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

Vicore Pharma Announces Presentations at the European Respiratory Society (ERS) International Congress 2023

Stockholm, September 6, 2023 – Vicore Pharma Holding AB…

Alchemab Therapeutics CEO to Present at Wells Fargo 2023 Healthcare Conference

Cambridge, UK, September 5, 2023 – Alchemab Therapeutics, an…

Six companies enter BioInnovation Institute’s Venture House program receiving additional financial support

BioInnovation Institute (BII), an international non-profit foundation…

Astraveus Appoints Microfluidic expert Etienne Fradet as Chief Technical Officer

• Etienne Fradet brings extensive industry expertise and a…

Lytix Biopharma presents first half and second quarter 2023 results

OSLO, Norway, August 31 2023. Lytix Biopharma – Lytix Biopharma…

The BioInnovation Institute welcomes eight new companies to its Venture Lab program

COPENHAGEN, Denmark, August 31, 2023 – BioInnovation Institute…

Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial

Oslo, 29 August 2023. Lytix Biopharma – Lytix Biopharma AS…

Vicore Pharma: Interim Report April-June 2023

Stockholm, August 24, 2023 - Vicore Pharma Holding AB (STO: VICO)…

Vicore reports data from EndoPAT® exploratory trial

Stockholm, August 22, 2023 – Vicore Pharma Holding AB (STO:…

Interim Report Q2, 2023

Filing for full approval of TARPEYO FINANCIAL SUMMARY FOR…

Novo Holdings participates in $290m strategic financing of Sangon Biotech

Novo Holdings, a leading international life science investor,…

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…

IO Biotech Announces 2023 Second Quarter Results

Achieved significant enrollment milestone in pivotal Phase…

IO Biotech Appoints Heidi Hunter to its Board of Directors

NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.